Shares of Rezolute Inc. surged 7.7% in pre-market trading to $4.50 on September 29 after Craig-Hallum reportedly upgraded the stock to Buy and slapped a $7 price target on the clinical-stage biotech — a figure that implies roughly 56% additional upside from current levels. The move puts a spotlight on whether one late-stage drug program can carry a company whose market value remains modest. Craig-Hallum Reverses Course on Rezolute With a $7 Target — Is One Trial Enough to Triple the Stock?

Reports emerged that Craig-Hallum upgraded Rezolute (RZLT) to Buy with a $7 price target on September 29, sending shares up 7.7% to $4.50 in pre-market trading. The move is a dramatic reversal for the same firm that, less than a year ago, slashed the stock in the opposite direction — and it hinges almost entirely on a single late-stage drug trial whose outcome remains months away.

  • The Same Analyst Who Cut the Stock to $2 Now Sees It at $7. In December 2025, Craig-Hallum downgraded Rezolute from Buy to Hold and slashed its price target to $2.00 from $18.00 after the company's Phase 3 trial in congenital hyperinsulinism (a genetic condition causing dangerously low blood sugar) flopped. As recently as June 2026, Craig-Hallum maintained its Hold rating. Today's upgrade to Buy at $7 signals the firm now believes Rezolute's other late-stage trial — in tumor-related hyperinsulinism — has materially changed the risk-reward calculus.

  • Early Trial Data Looks Encouraging, But the Study Isn't Done. In its ongoing Phase 3 upLIFT study, seven of eight enrolled participants met the primary endpoint's responder criterion, and six also stopped needing intravenous glucose. That's a strong signal, but the trial targets up to 16 hospitalized participants, with topline results expected before the end of 2026. Investors are effectively betting that the final readout will hold up.

  • Cash Is Burning Fast, Creating a Ticking Clock. Cash, equivalents, and marketable securities totaled $107.8 million at June 30, 2026, versus $167.9 million a year earlier — a roughly $60 million annual burn. Full fiscal year 2026 R&D expenses were $53.8 million. That gives Rezolute a cushion of less than two years, meaning trial results and any subsequent FDA filing need to progress quickly or the company will likely need to raise more money, diluting existing shareholders.

  • Wall Street Is Split, Making the Upgrade a Swing Vote. In June, Maxim set a $14 target, while Wedbush and BTIG sat at $6, and Citizens upgraded to Outperform. Craig-Hallum's shift from Hold to Buy adds another voice to the bull camp, but the stock's $4.50 price still sits well below the $7 target — a gap that will only close if the final trial data deliver.

The bottom line: Craig-Hallum is betting the upLIFT trial's early patient responses will hold across a broader group. If they do, Rezolute has a rare-disease drug with limited competition. If they don't, the stock — and its dwindling cash pile — face a much harder road.